Top

Current Cardiology Reports

Published in:

01-04-2022 | Stroke | Invasive Electrophysiology and Pacing (E. Kevin Heist, Section Editor)

Use of Prolonged Cardiac Rhythm Monitoring to Identify Atrial Fibrillation After Cryptogenic Stroke

Authors: Alexis T. Roy, Lee H. Schwamm, Aneesh B. Singhal

Published in: Current Cardiology Reports | Issue 4/2022

Abstract

Purpose of Review

Prolonged cardiac monitoring (PCM) improves detection of atrial fibrillation (AF) after cryptogenic stroke. We summarize current research supporting the use of PCM as part of the cryptogenic stroke evaluation, while highlighting areas that require more investigation.

Recent Findings

Despite increased AF detection with longer durations of PCM, more definitive research is needed to demonstrate how PCM improves clinical outcomes. The optimal type, timing, and length of cardiac monitoring after cryptogenic stoke remains unknown. Clinical calculators will be important to risk stratify which cryptogenic stroke patients are most likely to benefit from PCM. Currently, AF detection after cryptogenic stroke should prompt consideration of anticoagulation, but it is unclear if all durations and timing of AF after stroke should be treated the same.

Summary

PCM remains an important part of the cryptogenic stroke work up, and detection of AF allows for anticoagulation initiation. Additional research is needed to further refine our application of PCM to cryptogenic stroke.

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. https://doi.org/10.1161/cir.0000000000000950.CrossRefPubMed

Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439–58. https://doi.org/10.1016/s1474-4422(19)30034-1.

Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32(12):2735–40. https://doi.org/10.1161/hs1201.100209.CrossRefPubMed

Lee BI, Nam HS, Heo JH, Kim DI. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis. 2001;12(3):145–51. https://doi.org/10.1159/000047697.

Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015;14(9):903–13. https://doi.org/10.1016/s1474-4422(15)00132-5.CrossRefPubMedPubMedCentral

Saver JL. Clinical practice. Cryptogenic stroke N Engl J Med. 2016;374(21):2065–74. https://doi.org/10.1056/NEJMcp1503946.CrossRefPubMed

Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–87. https://doi.org/10.1016/s1474-4422(15)70027-x.CrossRefPubMed

Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86. https://doi.org/10.1056/NEJMoa1313600.CrossRefPubMed

Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467–77. https://doi.org/10.1056/NEJMoa1311376.CrossRefPubMed

10.

Israel C, Kitsiou A, Kalyani M, Deelawar S, Ejangue LE, Rogalewski A, et al. Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders. Thromb Haemost. 2017;117(10):1962–9. https://doi.org/10.1160/th17-02-0072.CrossRefPubMed

11.

Riordan M, Opaskar A, Yoruk A, Younis A, Ali A, McNitt S, et al. Predictors of atrial fibrillation during long-term implantable cardiac monitoring following cryptogenic stroke. J Am Heart Assoc. 2020;9(15): e016040. https://doi.org/10.1161/jaha.120.016040.CrossRefPubMedPubMedCentral

12.

Kamel H, Hegde M, Johnson DR, Gage BF, Johnston SC. Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke. 2010;41(7):1514–20. https://doi.org/10.1161/strokeaha.110.582437.CrossRefPubMed

13.

Giruparajah M, Bosch J, Vanassche T, Mattina K, Connolly SJ, Pater C, et al. Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke. Int J Stroke. 2015;10(7):1031–6. https://doi.org/10.1111/ijs.12509.CrossRefPubMed

14.

Rizos T, Quilitzsch A, Busse O, Haeusler KG, Endres M, Heuschmann P, et al. Diagnostic work-up for detection of paroxysmal atrial fibrillation after acute ischemic stroke: cross-sectional survey on German stroke units. Stroke. 2015;46(6):1693–5. https://doi.org/10.1161/strokeaha.115.009374.CrossRefPubMed

15.

Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–467. https://doi.org/10.1161/str.0000000000000375.CrossRefPubMed

16.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007.CrossRefPubMed

17.

Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43(12):3298–304. https://doi.org/10.1161/strokeaha.112.673558.CrossRefPubMed

18.

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342(8882):1255–62.

19.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8. https://doi.org/10.1161/01.str.22.8.983.CrossRefPubMed

20.

Tu HT, Campbell BC, Christensen S, Desmond PM, De Silva DA, Parsons MW, et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke. 2015;10(4):534–40. https://doi.org/10.1111/ijs.12007.CrossRefPubMed

21.

Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. https://doi.org/10.1161/01.str.24.1.35.

22.

Kamel H, Navi BB, Merkler AE, Baradaran H, Díaz I, Parikh NS, et al. Reclassification of ischemic stroke etiological subtypes on the basis of high-risk nonstenosing carotid plaque. Stroke. 2020;51(2):504–10. https://doi.org/10.1161/strokeaha.119.027970.CrossRefPubMed

23.

Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and embolic stroke of undetermined source. Stroke. 2021;52(3):1121–30. https://doi.org/10.1161/strokeaha.120.032002.CrossRefPubMedPubMedCentral

24.

Topcuoglu MA, Rocha EA, Siddiqui AK, Mills BB, Silva GS, Schwamm LH, et al. Isolated upper limb weakness from ischemic stroke: mechanisms and outcome. J Stroke Cerebrovasc Dis. 2018;27(10):2712–9. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.050.CrossRefPubMed

25.

Suo Y, Jing J, Meng X, Li Z, Pan Y, Jiang Y, et al. Inconsistent centralised versus non-centralised ischaemic stroke aetiology. Stroke Vasc Neurol. 2020;5(4):337–47. https://doi.org/10.1136/svn-2020-000576.CrossRefPubMedPubMedCentral

26.

Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38(11):2979–84. https://doi.org/10.1161/strokeaha.107.490896.CrossRefPubMed

27.

Yaghi S, Elkind MS. Cryptogenic stroke: a diagnostic challenge. Neurol Clin Pract. 2014;4(5):386–93. https://doi.org/10.1212/cpj.0000000000000086.CrossRefPubMedPubMedCentral

28.

Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, et al. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN international collaboration. Circulation. 2019;140(22):1834–50. https://doi.org/10.1161/circulationaha.119.040267.CrossRefPubMed

29.

Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80(17):1546–50. https://doi.org/10.1212/WNL.0b013e31828f1828.CrossRefPubMedPubMedCentral

30.

• Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201. https://doi.org/10.1056/NEJMoa1802686. One of two RTCs that failed to show AC improved stroke outcomes in ESUS patient.

31.

• Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17. https://doi.org/10.1056/NEJMoa1813959. One of two RTCs that failed to show AC improved stroke outcomes in ESUS patient.

32.

•• Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14(2):207–14. https://doi.org/10.1177/1747493018799981. Enrolling RTC to examine whether AC improves outcomes for ESUS patients with evidence of atrial cardiopathy.

33.

Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA(2)DS(2)-VASc score. Circulation. 2019;140(20):1639–46. https://doi.org/10.1161/circulationaha.119.041303.CrossRefPubMed

34.

Sana F, Isselbacher EM, Singh JP, Heist EK, Pathik B, Armoundas AA. Wearable devices for ambulatory cardiac monitoring: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(13):1582–92. https://doi.org/10.1016/j.jacc.2020.01.046.CrossRefPubMedPubMedCentral

35.

Zimetbaum P, Goldman A. Ambulatory arrhythmia monitoring: choosing the right device. Circulation. 2010;122(16):1629–36. https://doi.org/10.1161/circulationaha.109.925610.CrossRefPubMed

36.

Choe WC, Passman RS, Brachmann J, Morillo CA, Sanna T, Bernstein RA, et al. A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the cryptogenic stroke and underlying AF trial). Am J Cardiol. 2015;116(6):889–93. https://doi.org/10.1016/j.amjcard.2015.06.012.CrossRefPubMed

37.

Abdul-Rahim AH, Lees KR. Screening for atrial fibrillation after stroke or TIA. Lancet Neurol. 2015;14(4):345–7. https://doi.org/10.1016/s1474-4422(15)70039-6.CrossRefPubMed

38.

•• Buck BH, Hill MD, Quinn FR, Butcher KS, Menon BK, Gulamhusein S, et al. Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. Jama. 2021;325(21):2160–8. https://doi.org/10.1001/jama.2021.6128. RCT showing that ICM detects more AF than 30-day external cardiac monitor.

39.

Cuadrado-Godia E, Benito B, Ois A, Vallès E, Rodríguez-Campello A, Giralt-Steinhauer E, et al. Ultra-early continuous cardiac monitoring improves atrial fibrillation detection and prognosis of patients with cryptogenic stroke. Eur J Neurol. 2020;27(2):244–50. https://doi.org/10.1111/ene.14061.CrossRefPubMed

40.

Chew DS, Rennert-May E, Spackman E, Mark DB, Exner DV. Cost-effectiveness of extended electrocardiogram monitoring for atrial fibrillation after stroke: a systematic review. Stroke. 2020;51(7):2244–8. https://doi.org/10.1161/strokeaha.120.029340.CrossRefPubMed

41.

Sposato LA, Klein FR, Jáuregui A, Ferrúa M, Klin P, Zamora R, et al. Newly diagnosed atrial fibrillation after acute ischemic stroke and transient ischemic attack: importance of immediate and prolonged continuous cardiac monitoring. J Stroke Cerebrovasc Dis. 2012;21(3):210–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.06.010.CrossRefPubMed

42.

Higgins P, MacFarlane PW, Dawson J, McInnes GT, Langhorne P, Lees KR. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke. 2013;44(9):2525–31. https://doi.org/10.1161/strokeaha.113.001927.CrossRefPubMed

43.

Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF(RANDOMISED)): an open-label randomised controlled trial. Lancet Neurol. 2017;16(4):282–90. https://doi.org/10.1016/s1474-4422(17)30002-9.CrossRefPubMed

44.

Rodriguez-Campello A, Giralt-Steinhauer E, Ois A, Jimenez-Conde J, Avellaneda-Gomez C, Serra-Martinez M, et al. Atrial fibrillation detection and stroke recurrence in patients with early insertable cardiac monitor. a case-control study (AS21–027). Eur Stroke J. 2018;3:459.

45.

Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A simple score that predicts paroxysmal atrial fibrillation on outpatient cardiac monitoring after embolic stroke of unknown source. J Stroke Cerebrovasc Dis. 2018;27(6):1692–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.028.CrossRefPubMed

46.

Triantafyllou S, Katsanos AH, Dilaveris P, Giannopoulos G, Kossyvakis C, Adreanides E, et al. Implantable cardiac monitoring in the secondary prevention of cryptogenic stroke. Ann Neurol. 2020;88(5):946–55. https://doi.org/10.1002/ana.25886.CrossRefPubMed

47.

De Angelis MV, Di Stefano V, Franciotti R, Furia N, Di Girolamo E, Onofrj M, et al. Cryptogenic stroke and atrial fibrillation in a real-world population: the role of insertable cardiac monitors. Sci Rep. 2020;10(1):3230. https://doi.org/10.1038/s41598-020-60180-6.CrossRefPubMedPubMedCentral

48.

•• Tsivgoulis G, Katsanos AH, Grory BM, Köhrmann M, Ricci BA, Tsioufis K, et al. Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. Stroke. 2019;50(8):2175–80. https://doi.org/10.1161/strokeaha.119.025169. Meta-analysis providing preliminary evidence that PCM decreases stroke recurrence.

49.

• Haeusler KG, Kirchhof P, Kunze C, Tütüncü S, Fiessler C, Malsch C, et al. Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. Lancet Neurol. 2021;20(6):426–36. https://doi.org/10.1016/s1474-4422(21)00067-3. RCT showing that Holter monitor during index stroke admission does not decrease stroke recurrence.

50.

•• Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021. https://doi.org/10.1016/s0140-6736(21)01698-6. RCT showing ICM improves AF detection but does not decrease stroke recurrence in patients with vascular risk factors.

51.

Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke. 2015;46(5):1210–5. https://doi.org/10.1161/strokeaha.114.007763.CrossRefPubMed

52.

Suzuki S, Sagara K, Otsuka T, Kano H, Matsuno S, Takai H, et al. Usefulness of frequent supraventricular extrasystoles and a high CHADS2 score to predict first-time appearance of atrial fibrillation. Am J Cardiol. 2013;111(11):1602–7. https://doi.org/10.1016/j.amjcard.2013.01.335.CrossRefPubMed

53.

Todo K, Iwata T, Doijiri R, Yamagami H, Morimoto M, Hashimoto T, et al. Frequent premature atrial contractions in cryptogenic stroke predict atrial fibrillation detection with insertable cardiac monitoring. Cerebrovasc Dis. 2020;49(2):144–50. https://doi.org/10.1159/000505958.CrossRefPubMed

54.

Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015;11(3):323–31. https://doi.org/10.2217/fca.15.22.CrossRefPubMed

55.

Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology. 2016;86(3):261–9. https://doi.org/10.1212/wnl.0000000000002282.CrossRefPubMedPubMedCentral

56.

Poli S, Diedler J, Härtig F, Götz N, Bauer A, Sachse T, et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol. 2016;23(2):375–81. https://doi.org/10.1111/ene.12843.CrossRefPubMed

57.

Broughton ST, O’Neal WT, Salahuddin T, Soliman EZ. The influence of left atrial enlargement on the relationship between atrial fibrillation and stroke. J Stroke Cerebrovasc Dis. 2016;25(6):1396–402. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.02.004.CrossRefPubMed

58.

•• Ntaios G, Perlepe K, Lambrou D, Sirimarco G, Strambo D, Eskandari A, et al. Identification of patients with embolic stroke of undetermined source and low risk of new incident atrial fibrillation: the AF-ESUS score. Int J Stroke. 2021;16(1):29–38. https://doi.org/10.1177/1747493020925281. A clinical calculator that can help predict which patients may benefit from PCM for AF detection after ESUS.

59.

Kitsiou A, Sagris D, Schäbitz WR, Ntaios G. Validation of the AF-ESUS score to identify patients with embolic stroke of undetermined source and low risk of device-detected atrial fibrillation. Eur J Intern Med. 2021;89:135–6. https://doi.org/10.1016/j.ejim.2021.04.003.CrossRefPubMed

60.

Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12. https://doi.org/10.1016/s0140-6736(06)68845-4.CrossRefPubMed

61.

Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36(5):281–7. https://doi.org/10.1093/eurheartj/ehu307.CrossRefPubMed

62.

Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J. 2015;36(5):288–96. https://doi.org/10.1093/eurheartj/ehu359.

63.

Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37(20):1591–602. https://doi.org/10.1093/eurheartj/ehw007.CrossRefPubMed

64.

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2(5):474–80. https://doi.org/10.1161/circep.109.849638.CrossRefPubMed

65.

Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339–44. https://doi.org/10.1093/eurheartj/ehx042.CrossRefPubMed

66.

Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. JAMA Cardiol. 2018;3(7):601–8. https://doi.org/10.1001/jamacardio.2018.1176.CrossRefPubMedPubMedCentral

67.

Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, et al. Atrial high-rate episodes and stroke prevention. Europace. 2017;19(2):169–79. https://doi.org/10.1093/europace/euw279.CrossRefPubMed

68.

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–9. https://doi.org/10.1056/NEJMoa1105575.CrossRefPubMed

69.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. https://doi.org/10.1161/cir.0000000000000665.CrossRefPubMed

70.

Tran RT, Rankin AJ, Abdul-Rahim AH, Lip GY, Rankin AC, Lees KR. Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists. J R Coll Physicians Edinb. 2016;46(2):87–92. https://doi.org/10.4997/jrcpe.2016.204.CrossRefPubMed

71.

Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-354. https://doi.org/10.1161/circulationaha.106.177292.CrossRefPubMed

72.

Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol. 2009;20(3):241–8. https://doi.org/10.1111/j.1540-8167.2008.01320.x.CrossRefPubMed

73.

Liantinioti C, Tympas K, Katsanos AH, Parissis J, Chondrogianni M, Zompola C, et al. Duration of paroxysmal atrial fibrillation in cryptogenic stroke is not associated with stroke severity and early outcomes. J Neurol Sci. 2017;376:191–5. https://doi.org/10.1016/j.jns.2017.03.038.CrossRefPubMed

74.

Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137–45. https://doi.org/10.1016/j.ahj.2017.04.008.CrossRefPubMed

75.

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12–8. https://doi.org/10.1016/j.ahj.2017.04.015.CrossRefPubMedPubMedCentral

76.

Tahsili-Fahadan P, Geocadin RG. Heart-brain axis: effects of neurologic injury on cardiovascular function. Circ Res. 2017;120(3):559–72. https://doi.org/10.1161/circresaha.116.308446.CrossRefPubMed

77.

Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9. https://doi.org/10.1161/circulationaha.113.007825.CrossRefPubMed

78.

Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36(26):1660–8. https://doi.org/10.1093/eurheartj/ehv115.CrossRefPubMed

79.

Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342: d124. https://doi.org/10.1136/bmj.d124.CrossRefPubMedPubMedCentral

80.

Sposato LA, Cerasuolo JO, Cipriano LE, Fang J, Fridman S, Paquet M, et al. Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. Neurology. 2018;90(11):e924–31. https://doi.org/10.1212/wnl.0000000000005126.CrossRefPubMed

81.

•• Bernstein RA, Kamel H, Granger CB, Piccini JP, Sethi PP, Katz JM, et al. Effect of long-term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: the STROKE-AF randomized clinical trial. Jama. 2021;325(21):2169–77. https://doi.org/10.1001/jama.2021.6470. RTC showing that patients with non-cardioembolic stroke etiologies have high rates of AF detection with PCM.

Title: Use of Prolonged Cardiac Rhythm Monitoring to Identify Atrial Fibrillation After Cryptogenic Stroke
Authors: Alexis T. Roy
Lee H. Schwamm
Aneesh B. Singhal
Publication date: 01-04-2022
Publisher: Springer US
Keywords: Stroke
Atrial Fibrillation
Published in: Current Cardiology Reports / Issue 4/2022
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-022-01652-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Use of Prolonged Cardiac Rhythm Monitoring to Identify Atrial Fibrillation After Cryptogenic Stroke

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2022

Interference by Modern Smartphones and Accessories with Cardiac Pacemakers and Defibrillators

Radial Artery Access for Acute Coronary Syndromes: a Review of Current Evidence

MRI-Guided Cardiac Catheterization in Congenital Heart Disease: How to Get Started

Is Sedentary Behavior a Novel Risk Factor for Cardiovascular Disease?

Mesenchymal Stromal Cell Exosomes in Cardiac Repair

Artificial Intelligence to Improve Risk Prediction with Nuclear Cardiac Studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page